Antimalarial Pharmacology and Therapeutics of Atovaquone 1 2
暂无分享,去创建一个
D. Lalloo | G. Nixon | G. Biagini | A. Shone | S. Ward | P. O’Neill | D. Moss | N. Fisher
[1] N. White,et al. The effects of serum lipids on the in vitro activity of lumefantrine and atovaquone against Plasmodium falciparum , 2012, Malaria Journal.
[2] D. Kyle,et al. Lead optimization of 3-carboxyl-4(1H)-quinolones to deliver orally bioavailable antimalarials. , 2012, Journal of medicinal chemistry.
[3] J. Hemingway,et al. Generation of quinolone antimalarials targeting the Plasmodium falciparum mitochondrial respiratory chain for the treatment and prophylaxis of malaria , 2012, Proceedings of the National Academy of Sciences.
[4] Sowmya R. Rao,et al. Global TravEpiNet: a national consortium of clinics providing care to international travelers--analysis of demographic characteristics, travel destinations, and pretravel healthcare of high-risk US international travelers, 2009-2011. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[5] H. Ranson,et al. Cytochrome b Mutation Y268S Conferring Atovaquone Resistance Phenotype in Malaria Parasite Results in Reduced Parasite bc1 Catalytic Turnover and Protein Expression , 2012, The Journal of Biological Chemistry.
[6] D. Kyle,et al. Synthesis, antimalarial activity, and structure-activity relationship of 7-(2-phenoxyethoxy)-4(1H)-quinolones. , 2011, Journal of medicinal chemistry.
[7] F. Wit,et al. Lower atovaquone and proguanil concentrations in patients taking efavirenz, lopinavir + ritonavir or atazanavir + ritonavir , 2011 .
[8] P. Narciso,et al. Marked increase in etravirine and saquinavir plasma concentrations during atovaquone/proguanil prophylaxis , 2011, Malaria Journal.
[9] A. Thomas,et al. Towards an In Vitro Model of Plasmodium Hypnozoites Suitable for Drug Discovery , 2011, PloS one.
[10] D. Koop,et al. Optimization of endochin-like quinolones for antimalarial activity. , 2011, Experimental parasitology.
[11] H. Balaram,et al. Metabolic Fate of Fumarate, a Side Product of the Purine Salvage Pathway in the Intraerythrocytic Stages of Plasmodium falciparum* , 2011, The Journal of Biological Chemistry.
[12] S. Dean,et al. A Potential Interaction between Warfarin and Atovaquone , 2011, The Annals of pharmacotherapy.
[13] F. Zsila,et al. Combination of chiroptical, absorption and fluorescence spectroscopic methods reveals multiple, hydrophobicity-driven human serum albumin binding of the antimalarial atovaquone and related hydroxynaphthoquinone compounds. , 2010, Organic & biomolecular chemistry.
[14] G. Biagini,et al. Inhibiting Plasmodium cytochrome bc1: a complex issue. , 2010, Current opinion in chemical biology.
[15] C. Guillemette,et al. Glucuronidation of the Antiretroviral Drug Efavirenz by UGT2B7 and an in Vitro Investigation of Drug-Drug Interaction with Zidovudine , 2009, Drug Metabolism and Disposition.
[16] Sozanne R. Solmaz,et al. Structure of Complex III with Bound Cytochrome c in Reduced State and Definition of a Minimal Core Interface for Electron Transfer* , 2008, Journal of Biological Chemistry.
[17] D. Lalloo,et al. Preventing malaria in travellers , 2008, BMJ : British Medical Journal.
[18] Andrew Owen,et al. Acridinediones: Selective and Potent Inhibitors of the Malaria Parasite Mitochondrial bc1 Complex , 2008, Molecular Pharmacology.
[19] D. Kramer,et al. A drug-selected Plasmodium falciparum lacking the need for conventional electron transport. , 2008, Molecular and biochemical parasitology.
[20] David Hinrichs,et al. Antimalarial quinolones: synthesis, potency, and mechanistic studies. , 2008, Experimental parasitology.
[21] J. Le bras,et al. Plasmodium falciparum Malaria and Atovaquone-Proguanil Treatment Failure , 2008, Emerging infectious diseases.
[22] P. Hunter,et al. A systematic review and meta-analysis of the effectiveness and safety of atovaquone proguanil (Malarone) for chemoprophylaxis against malaria. , 2007, The Journal of antimicrobial chemotherapy.
[23] S. Meshnick,et al. Modeling the molecular basis of atovaquone resistance in parasites and pathogenic fungi. , 2007, Trends in parasitology.
[24] I. Mcintosh,et al. Metabolism and Disposition in Humans of Raltegravir (MK-0518), an Anti-AIDS Drug Targeting the Human Immunodeficiency Virus 1 Integrase Enzyme , 2007, Drug Metabolism and Disposition.
[25] Joanne M. Morrisey,et al. Specific role of mitochondrial electron transport in blood-stage Plasmodium falciparum , 2007, Nature.
[26] J. Lelièvre,et al. Prevalence of Plasmodium falciparum cytochrome b gene mutations in isolates imported from Africa, and implications for atovaquone resistance. , 2006, Transactions of the Royal Society of Tropical Medicine and Hygiene.
[27] J. Le bras,et al. Clinical atovaquone-proguanil resistance of Plasmodium falciparum associated with cytochrome b codon 268 mutations. , 2006, Microbes and infection.
[28] G. Biagini,et al. Functional Characterization and Target Validation of Alternative Complex I of Plasmodium falciparum Mitochondria , 2006, Antimicrobial Agents and Chemotherapy.
[29] S. Owusu‐Ofori,et al. Atovaquone-proguanil for treating uncomplicated malaria. , 2005, The Cochrane database of systematic reviews.
[30] N. Suttorp,et al. Malarone treatment failure not associated with previously described mutations in the cytochrome b gene , 2004, Malaria Journal.
[31] K. Kain,et al. Genetic confirmation of atovaquone-proguanil-resistant Plasmodium falciparum malaria acquired by a nonimmune traveler to East Africa. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[32] A. Baggish,et al. Antiparasitic Agent Atovaquone , 2002, Antimicrobial Agents and Chemotherapy.
[33] L. Trepanier,et al. Inhibition by atovaquone of CYP2C9-mediated sulphamethoxazole hydroxylamine formation , 2002, European Journal of Clinical Pharmacology.
[34] M. Ashton,et al. Time-dependent pharmacokinetics and drug metabolism of atovaquone plus proguanil (Malarone) when taken as chemoprophylaxis , 2002, European Journal of Clinical Pharmacology.
[35] G. Butcher,et al. Malarone treatment failure and in vitro confirmation of resistance of Plasmodium falciparum isolate from Lagos, Nigeria , 2002, Malaria Journal.
[36] D. Back,et al. CYP3A4-mediated hepatic metabolism of the HIV-1 protease inhibitor saquinavir in vitro , 2002, Xenobiotica; the fate of foreign compounds in biological systems.
[37] J. Montaner,et al. Atovaquone suspension for treatment of Pneumocystis carinii pneumonia in HIV-infected patients , 2001, AIDS.
[38] Q. Cheng,et al. Mutations in Plasmodium falciparumCytochrome b That Are Associated with Atovaquone Resistance Are Located at a Putative Drug-Binding Site , 2000, Antimicrobial Agents and Chemotherapy.
[39] Christos Reppas,et al. Forecasting the In Vivo Performance of Four Low Solubility Drugs from Their In Vitro Dissolution Data , 1999, Pharmaceutical Research.
[40] T. Cheung. Overdose of atovaquone in a patient with AIDS. , 1999, AIDS.
[41] C. Gissi,et al. Nucleotide Substitution Rate of Mammalian Mitochondrial Genomes , 1999, Journal of Molecular Evolution.
[42] David R. Williams,et al. Synthesis of Atovaquone. , 1999 .
[43] K. K. Seymour,et al. dCTP levels are maintained in Plasmodium falciparum subjected to pyrimidine deficiency or excess. , 1997, Annals of tropical medicine and parasitology.
[44] N. White,et al. Assessment of the pharmacodynamic properties of antimalarial drugs in vivo , 1997, Antimicrobial agents and chemotherapy.
[45] P. Rolan,et al. Disposition of atovaquone in humans , 1997, Antimicrobial agents and chemotherapy.
[46] C. Canfield,et al. Population pharmacokinetics of atovaquone in patients with acute malaria caused by Plasmodium falciparum , 1997, Clinical pharmacology and therapeutics.
[47] A. Vaidya,et al. Atovaquone, a Broad Spectrum Antiparasitic Drug, Collapses Mitochondrial Membrane Potential in a Malarial Parasite* , 1997, The Journal of Biological Chemistry.
[48] P. Rolan,et al. Atovaquone has no effect on the pharmacokinetics of phenytoin in healthy male volunteers. , 1996, British journal of clinical pharmacology.
[49] P. Rolan,et al. Single-dose and steady-state pharmacokinetics of a novel microfluidized suspension of atovaquone in human immunodeficiency virus-seropositive patients , 1996, Antimicrobial agents and chemotherapy.
[50] B. Sadler,et al. Atovaquone inhibits the glucuronidation and increases the plasma concentrations of zidovudine , 1996, Clinical pharmacology and therapeutics.
[51] P. Chiodini,et al. Evaluation of atovaquone in the treatment of patients with uncomplicated Plasmodium falciparum malaria. , 1995, The Journal of antimicrobial chemotherapy.
[52] J. Flaherty,et al. ATOVAQUONE: A Review , 1993, The Annals of pharmacotherapy.
[53] J. Falloon,et al. Comparison of atovaquone (566C80) with trimethoprim-sulfamethoxazole to treat Pneumocystis carinii pneumonia in patients with AIDS. , 1993, The New England journal of medicine.
[54] A. Hudson,et al. Atovaquone - a novel broad-spectrum anti-infective drug. , 1993, Parasitology today.
[55] M. Fry,et al. Site of action of the antimalarial hydroxynaphthoquinone, 2-[trans-4-(4'-chlorophenyl) cyclohexyl]-3-hydroxy-1,4-naphthoquinone (566C80). , 1992, Biochemical pharmacology.
[56] R. Bevan,et al. Catabolism of 3'-azido-3'-deoxythymidine in hepatocytes and liver microsomes, with evidence of formation of 3'-amino-3'-deoxythymidine, a highly toxic catabolite for human bone marrow cells. , 1991, Molecular pharmacology.
[57] A. Hudson,et al. In vitro activity of 2-cycloalkyl-3-hydroxy-1,4-naphthoquinones against Theileria, Eimeria and Plasmodia species , 1986 .
[58] R. Williams,et al. Novel anti-malarial hydroxynaphthoquinones with potent broad spectrum anti-protozoal activity , 1985, Parasitology.
[59] G. Fawaz,et al. The effect of lapinone (M-2350) on P. vivax infection in man. , 1951, The American journal of tropical medicine and hygiene.
[60] L. Fieser,et al. Naphthoquinone antimalarials; correlation of structure and activity against P. lophurae in ducks. , 1948, Journal of the American Chemical Society.
[61] K. McKeage,et al. Atovaquone/proguanil: a review of its use for the prophylaxis of Plasmodium falciparum malaria. , 2003, Drugs.
[62] J. Hochman,et al. Influence of P-glycoprotein on the transport and metabolism of indinavir in Caco-2 cells expressing cytochrome P-450 3A4. , 2000, The Journal of pharmacology and experimental therapeutics.
[63] H. Webster,et al. Clinical studies of atovaquone, alone or in combination with other antimalarial drugs, for treatment of acute uncomplicated malaria in Thailand. , 1996, The American journal of tropical medicine and hygiene.
[64] K. Goa,et al. Atovaquone. A review of its pharmacological properties and therapeutic efficacy in opportunistic infections. , 1995, Drugs.
[65] B. Weatherley,et al. Examination of some factors responsible for a food-induced increase in absorption of atovaquone. , 1994, British journal of clinical pharmacology.
[66] W. Gutteridge,et al. 566C80: a potent broad spectrum anti-infective agent with activity against malaria and opportunistic infections in AIDS patients. , 1991, Drugs under experimental and clinical research.
[67] D. Hammond,et al. Inhibition of pyrimidine biosynthesis de novo in Plasmodium falciparum by 2-(4-t-butylcyclohexyl)-3-hydroxy-1,4-naphthoquinone in vitro. , 1985, Molecular and biochemical parasitology.
[68] M. Mungthin,et al. In vitro atovaquone/proguanil susceptibility and characterization of the cytochrome b gene of Plasmodium falciparum from different endemic regions of Thailand , 2008, Malaria Journal.